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Introduction
Macrophage activations syndrome (MAS) in systemic
juvenile idiopathic arthritis (sJIA) can pursue a rapidly
fatal course. However, diagnosis is often challenging as
MAS may be mimicked by confusable conditions, such
as flares of sJIA or systemic infections. In addition, the
clinical spectrum of MAS is known to be heterogeneous.
Objectives
To seek insights into the heterogeneity of MAS by com-
paring characteristics of patients enrolled in a large mul-
tinational survey in relation to geographic origin,
specialty of attending physician, detection of hemopha-
gocytosis (HP), and outcome.
Methods
Patient data were collected retrospectively by pediatric
rheumatologists (PR) or pediatric hemato-oncologists
(PHO). Clinical features, treatments and outcome were
compared between groups by Mann-Whitney or chi-
square tests. “Severe course” was defined as ICU admission
or death.
Results
362 patients with MAS in sJIA were collected by 95
investigators from 33 countries. 179 patients (49.4%)
were enrolled in Europe (EU), 72 (19.9%) in North
America (NA) and 111 (30.7%) in other continents
(OC). 79 (21.8%) patients were included by PHO. HP was
detected in 44% of patients and was not detected or looked
for in 56%. Severe course was reported in 92 (25%)
patients. Comparison by geographic origin showed a lower
frequency of CNS disease in EU patients. NA physicians
used more frequently ivIg and biologics. Patients entered
by PHO had greater frequency of multiorgan failure and
were given more commonly biologics and etoposide,
whereas PR used more frequently cyclosporine (CsA).
Patients with HP had shorter duration of sJIA at MAS
onset, higher prevalence of hepatosplenomegaly, lower
levels of platelets and fibrinogen and received more fre-
quently CsA, ivIg and etoposide. Patients with severe
course were older, had longer duration of sJIA at MAS
onset, greater frequency of haemorrhages and CNS dys-
function, lower levels of ESR, albumin and fibrinogen,
higher levels of LDH and D-dimer and were treated more
commonly with CsA, ivIg and etoposide.
Conclusion
Clinical and histopathologic features of MAS in sJIA were
overall comparable among patients from different conti-
nents, whereas there was disparity in therapeutic choices
made by specialists practicing in different geographic areas
or fields. Patients with detection of HP or severe course
had more acute clinical picture and were treated more
aggressively.
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